Markets:

Overview

News

Currencies

International

Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ:FATE)

1.530 +0.280 (+22.40%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years? ↗

January 14, 2022

One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t...

Via Benzinga

Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today ↗

January 05, 2022

Fate Therapeutics (NASDAQ:FATE) has outperformed the market over the past 5 years by 64.83% on an annualized basis. Buying $100 In FATE: 5 years ago, an investor could have...

Via Benzinga

10 Biggest Price Target Changes For Wednesday ↗

December 15, 2021

Barclays boosted the price target on Sysco Corporation (NYSE:

Via Benzinga

The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks ↗

December 14, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021 ↗

December 15, 2021

Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:

Via Benzinga

Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma ↗

December 14, 2021

Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the...

Via Benzinga

Hedge Funds Are Selling Vontier Corporation ↗

December 11, 2021

Vontier Corporation investors should pay attention to a decrease in activity from the world’s largest hedge funds recently. Vontier Corporation was in 31 hedge funds’ portfolios at the end of...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗

December 07, 2021

Upgrades For CarMax Inc (NYSE:

Via Benzinga

Cathie Wood Likes Fate Therapeutics, Should You? ↗

December 01, 2021

The biotech has an interesting pipeline, but it's all early stage products.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021 ↗

November 09, 2021

Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE:

Via Benzinga

Fate Therapeutics, inc (FATE) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

FATE earnings call for the period ending October 31, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

3 Biotech Stocks to Watch Now ↗

October 12, 2021

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so. Most biotech stocks trade at low prices and...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain ↗

September 14, 2021

Positive news versus poor clinical trial results may determine the future of Fate Therapeutics.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2021 ↗

August 26, 2021

Upgrades Scotiabank upgraded the previous rating for Enerplus Corp (NYSE:

Via Benzinga

Benchmarks Pivot Higher Ahead of Volatile Week's End ↗

August 20, 2021

The major indexes rebounded from their pre-market slide soon after the open, with help from big-name tech names, though all three are still on track for weekly losses.

Via Talk Markets

58 Biggest Movers From Friday ↗

August 23, 2021

Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 20, 2021

Gainers Regencell Bioscience (NASDAQ:RGC) shares rose 175.07% to $17.33 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 277....

Via Benzinga

38 Stocks Moving In Friday's Mid-Day Session ↗

August 20, 2021

Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing...

Via Benzinga

Why Fate Therapeutics Stock Is Sliding Today ↗

August 20, 2021

The positive results the company announced after the bell yesterday didn't meet some lofty expectations.

Via The Motley Fool

Mid-Morning Market Update: Markets Rise; Deere Beats Q3 Expectations ↗

August 20, 2021

Following the market opening Friday, the Dow traded up 0.42% to 35,041.98 while the NASDAQ rose 0.86% to 14,667.29. The S&P also rose, gaining 0.52% to 4,428.90. The U.S. has...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 20, 2021

Gainers Geovax Labs (NASDAQ:GOVX) shares...

Via Benzinga

11 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 20, 2021

Gainers Geovax Labs (NASDAQ:GOVX) stock moved upwards by 74.65% to $7.51. The market value of their outstanding shares is at $47.5 million. Agile Therapeutics (NASDAQ:AGRX...

Via Benzinga

Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response ↗

August 20, 2021

Fate Therapeutics Inc (NASDAQ: FATE) revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed / refractory B-cell lymphoma. At the 2021...

Via Benzinga

Fate Stock Collapses As Investors Question Its Cancer Drug's Durability ↗

August 19, 2021

Fate Therapeutics unveiled mixed results for its lymphoma treatment late Thursday, and Fate stock crumbled in after-hours action.

Via Investor's Business Daily

The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow ↗

August 15, 2021

Biopharma stocks retreated in the week ending Aug. 13, defying the optimism that was found in the broader market. Earnings continued to dominate the headlines, with small-...

Via Benzinga

Topics Initial Public Offering

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck ↗

August 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

Fate Therapeutics, inc (FATE) Q2 2021 Earnings Call Transcript ↗

August 06, 2021

FATE earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.